

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

APPLICANT: Richard J. Greff

JAN 21 2004

SERIAL NO.: 10/068,812

OFFICIAL

FILING DATE: 02/04/2002

TITLE: CROSS-LINKED GELATIN COMPOSITION COMPRISING A
WETTING AGENT

EXAMINER: GHALI, ISSIS A D

ART UNIT: 1615

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Alexandria, VA 22313-1450, on the date printed below:

Date: 9/23/03Name: Ruth Rodriguez

Ruth Rodriguez

COMMISSIONER FOR PATENTS
P.O. Box 1450, ALEXANDRIA, VA 22313-1450INFORMATION DISCLOSURE STATEMENT

Each item of information listed in the attached FORM PTO-1449, for which a copy of each is attached, may be material to the examination of the above-identified application and is, therefore, submitted in compliance with the duty of disclosure defined in 37 CFR §§ 1.56, 1.97 and 1.98. The Examiner is requested to make these items of official record in this application.

This Information Disclosure Statement under 37 CFR §§ 1.56, 1.97 and 1.98 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these items constitutes prior art.

I

This statement is filed pursuant to:

(X) 37 C.F.R. § 1.97(b).

This information disclosure statement is filed either (1) within three months of the filing date of a national application other than a continued prosecution application under §1.53(d); (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; (3) before the mailing date of a first office action on the merits, or (4) before the mailing of a first office action after the filing of a Request for Continued Examination under 37 C.F.R. § 1.114, whichever event occurs last.

Accordingly, this information disclosure statement requires no fee and no certification.

() 37 C.F.R. § 1.97(c).

This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97 (b), but before the mailing date of either (1) a final action under 37 C.F.R. § 1.113; (2) a notice of allowance under 37 C.F.R. § 1.311; or (3) an action that otherwise closes prosecution in the application.

Accordingly, this information disclosure statement requires either the fee specified in 37 C.F.R. § 1.17 (p) for submission of an information disclosure statement under 37 C.F.R. § 1.97 (c) (\$180); or a certification according to 37 C.F.R. § 1.97 (e).

() 37 C.F.R. § 1.97(d).

This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97 (c).

Accordingly, this information disclosure statement requires the fee specified in 37 C.F.R. § 1.17 (p) to consider an information disclosure statement under 37 C.F.R. § 1.97(d) (\$180), and a certification according to 37 C.F.R. § 1.97(e).

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. § 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this paper as a conditional petition for acceptance of the information disclosure statement.

II

No fee is due.

The fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c) is enclosed (\$180).

Please charge any additional required fee or credit any overpayment to our deposit account number 50-1698. An additional copy of this page is enclosed.

III

Pursuant to 37 C.F.R. § 1.97(e), I certify:


No certification is necessary.

(1) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.

(2) No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c), more than three months prior to the filing of the statement.

Respectfully submitted,
THELEN REID & PRIEST LLP

Dated: September 22, 2003



Adrienne Yeung
Reg. No. 44,000

THELEN REID & PRIEST LLP
P.O. Box 640640
San Jose, CA 95164-0640
(408) 292-5800 direct dial
(408) 287-8040 direct fax

Form PTO 1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office				Atty. Docket No. 34298-122	Serial No. 10/068,812		
Information Disclosure Statement by Applicant (Use several sheets if necessary)				Applicant: Richard J. Greff Filed: 02/04/02 Group: 1615			
U.S. Patent Documents							
Init.		Document No.	Date	Name	Class	Subclass	Filing Date
A		581,235		Kenyon			4/1897
B		1,578,517		Hein			3/1926
C		2,086,580		Shirley			7/1937
D		2,492,458		Bering, Jr.			12/1946
E		2,597,011		MacMasters et al.			5/1952
F		2,680,442		Linzmayer			6/1954
G		2,761,446		Reed			9/1956
H		2,814,294		Figge			11/1957
I		2,824,092		Thompson			2/1959
J		3,157,524		Artandi			11/64
K		3,724,465		Duchane			
L		4,000,741		Binard, et al.			1/77
M		4,211,323		Olsen			7/80
N		4,218,155		Weidner			8/80
O		4,323,072		Rosenbluth, et al.			4/82
P		4,340,066		Shah			7/82
Q		4,390,018		Zuloowski			6/83
R		4,515,637		Cioca			5/85
S		4,587,969		Gillis			5/86
T		4,588,395		Lemelson			5/86
U		4,619,261		Guerriero			10/86
V		4,619,913		Luck, et al.			10/86
W		4,645,488		Matukas			2/87
X		4,744,364		Kensey			8/89
Y		4,790,819		Li, et al.			12/88
Z		4,852,568		Kensey			8/89
A1		4,890,612		Kensey			1/90
B1		4,900,303		Lemelson			2/90
C1		4,929,246		Sinofaky			5/90
D1		4,936,835		Haaga			6/90
E1		4,950,234		Fujioka et al.			8/90
F1		5,007,895		Burnett			4/91
Examiner				Date Considered			
Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.							

Page 2 of 7

Form PTO 1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office				Atty. Docket No. 34298-122	Serial No. 10/068,812		
Information Disclosure Statement by Applicant				Applicant: Richard J. Greff			
(Use several sheets if necessary)				Filed: 02/04/02	Group: 1615		
U.S. Patent Documents							
Init.		Document No.	Date	Name	Class	Subclass	Filing Date
	G1	5,021,059		Kensey et al.			6/91
	H1	5,053,046		Janese			10/91
	I1	5,061,274		Kensey			10/91
	J1	5,080,655		Haaga			1/92
	K1	5,108,421		Fowler			4/92
	L1	5,163,904		Lampropoulous, et al.			11/92
	M1	5,167,624		Butler, et al.			12/92
	N1	5,192,300		Fowler			3/93
	O1	5,192,301		Kamiya, et al.			3/93
	P1	5,195,988		Haaga			3/93
	Q1	5,220,926		Jones			6/93
	R1	5,221,259		Weldon, et al.			6/93
	S1	5,275,616		Fowler			1/94
	T1	5,310,407		Casale			5/94
	U1	5,322,515		Karas, et al.			6/94
	V1	5,325,857		Nabai, et al.			7/94
	W1	5,334,216		Vidal, et al.			8/94
	X1	5,366,480		Corriveau, et al.			11/94
	Y1	5,370,656		Shevel			12/94
	Z1	5,383,896		Gershony, et al.			1/95
	A2	5,383,899		Hammerslag			1/95
	B2	5,385,550		Su, et al.			1/95
	C2	5,388,588		Nabai, et al.			2/95
	D2	5,391,183		Janzen et al.			2/95
	E2	5,417,699		Klein			5/95
	F2	5,437,292		Kipshidze			8/95
	G2	5,437,631		Janzen			8/95
	H2	5,443,481		Lee			8/95
	I2	5,467,780		Nabai, et al.			11/95
	J2	5,478,352		Fowler			12/95
	K2	5,479,936		Nabai, et al.			1/95
	L2	5,486,195		Myers			1/96
Examiner				Date Considered			
Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.							

Page 3 of 7

Form PTO 1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office				Atty. Docket No. 34298-122	Serial No. 10/068,812		
Information Disclosure Statement by Applicant (Use several sheets if necessary)				Applicant: Richard J. Greff			
				Filed: 02/04/02	Group: 1615		
U.S. Patent Documents							
Init.	Document No.	Date	Name	Class	Subclass	Filing Date	
M2	5,490,736		Haber			2/96	
N2	5,522,840		Krajicek			6/96	
O2	5,522,850		Yomtov, et al.			6/96	
P2	5,526,822		Burbank et al.			6/96	
Q2	5,527,332		Clement			6/96	
R2	5,529,577		Hammerslag			6/96	
S2	5,540,715		Katseros, et al.			6/96	
T2	5,542,914		Van Iten				
U2	5,545,178		Kensey, et al.			8/96	
V2	5,558,853		Quay			9/96	
W2	5,591,204		Janzen, et al.			1/97	
X2	5,591,205		Fowler			1/97	
Y2	5,601,602		Fowler			2/97	
Z2	5,645,566		Brennenman, et al.			7/97	
A3	5,653,730		Hammerslag			8/97	
B3	5,665,107		Hammerslag			9/97	
C3	5,649,547		Ritchart, et al.			7/97	
D3	5,676,689		Kensey			10/97	
E3	5,681,279		Roper, et al.			10/97	
F3	5,716,375		Fowler			02/98	
G3	5,725,498		Janzen et al.			3/98	
H3	5,741,223		Janzen et al.			04/98	
I3	5,769,086		Ritchart et al.			6/98	
J3	5,775,333		Burbank et al.			7/98	
K3	5,800,389		Burney et al.			9/98	
L3	5,810,806		Ritchart et al.			9/98	
M3	5,830,130		Janzen et al.			11/98	
N3	5,902,310		Foerster et al.			5/99	
O3	5,858,008		Capaccio			1/99	
P3	6,027,471		Fallon et al.			2/00	
Q3	6,027,482		Imbert			2/00	
R3	6,161,034		Burbank et al.			12/00	
Examiner				Date Considered			

Page 4 of 7

Page 5 of 7

Form PTO 1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 34298-122	Serial No. 10/068,812
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant: Richard J. Greff Filed: 02/04/02 Group: 1615	
P4	Allison, D., et al., "Percutaneous liver biopsy and track embolization with steel coils", Radiology, Vol. 169, pp. 261-263, (1998)		
Q4	J. Bryne Review Article: Endovascular treatments for intracranial aneurysms, 1996 The British journal of radiology; 98,891-899		
R4	Chuang, V., et al., "Sheath needle for liver biopsy in high-risk patients", Radiology, vol. 166, pp. 261-262 (1988)		
S4	John T. Correll, et al., A new Physiologically absorbable sponge		
T4	John T. Correll, et al. Biologic investigations of new absorbable sponge; pg 585		
U4	Fandrich, C., et al. "Small gauge gelfoam plug liver biopsy in high risk patients", Australian Radiology, vol. 40, pp. 230-234 (1996)		
V4	Foran, JPM, et al. "Early mobilisation after percutaneous cardiac catheterisation using collagen plug (vasoseal) haemostasis" BRHeart, vol. 69, pp. 424-429 (1993)		
W4	Gibbs, JSR, "Femoral arterial hemostasis" J. Interventional card, vol. 5, pp. 85-88 (1992)		
X4	Journal of interventional cardiology volume 5 no. 2 June		
Y4	Kassell, et al. Size of Intracranial aneurysm; vol. 12, no. 3, (1983)		
Z4	Kierneneiji, F., et al., "Improved anticoagulation management after Palmaz Schatz coronary stent implantation by sealing the arterial puncture site with vascular hemostasis device", Catheterization and Cardiovascular diagnosis, vol. 30, pp. 1685- 1692 (1995)		
A5	Kussmaul, WG, "Rapid arterial hemostasis", J. Am. Coll. Card., vol. 25, pp. 1685-1692 (1995)		
B5	Pharmacia & Upjohn manufacturer brochure "gelfoam sterile sponge, sterile powder and sterile film. pp 1-34 (May 1997)		
C5	Pharmacia & Upjohn manufacturer brochure "gelfoam sterile powder ", (Feb. 1996)		
D5	Pharmacia & Upjohn manufacturer brochure, "gelfoam sterile powder" (March 1996)		
E5	Pharmacia & Upjohn manufacturer brochure (Sep. 1996)		
F5	Pharmacia & Upjohn manufacturer specification, "Gelfoam sterile sponge, sterile powder and sterile film" pp. 1-23 (Nov. 1996)		
G5			
H5	Riley, SA, Percutaneous liver biopsy with plugging of needle track: a safe method for use in patients with impaired coagulation, The lancet, p. 436 (1964)		
I5	Sanborn, T. Multicenter randomized trial comparing percutaneous collagen hemostasis device with conventional manual compression after diagnostic angiography and angioplasty , J. Am. Coll. Card., Vol. 22, pp. 1273-1279, (1993)		
Examiner		Date Considered	
Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.			

Page 6 of 7

Form PTO 1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 34298-122	Serial No. 10/068,812
Information Disclosure Statement by Applicant	Applicant: <u>Richard J. Greff</u>	
(Use several sheets if necessary)	Filed: 02/04/02	Group: 1615

Foreign Documents

Translation								
Init.		Document No.	Date	Country	Class	Subclass	Yes	No
	J5	0032826	07/81	EP				
	K5	0476178	3/92	EP				
	L5	0482350	04/92	EP				
	M5	0557963	02/93	EP				
	N5	0637431	11/94	EP				
	O5	1509023	04/78	UK				
	P5	1569660		UK				
	Q5	1088709A	04/84	Russia				
	R5	782814	11/80	Russia				
	S5	2641692	07/90	France				
	T5	WO 91/12847	09/91	PCT				
	U5	WO 94/02072		PCT				
	V5	WO 96/08208	03/96	PCT				
	W5	WO 98/06346	02/98	PCT				
	X5	WO 99/66834	12/99	PCT				
	Y5	WO 94/28800	12/94	PCT				
	Z5	WO 95/28124	10/95	PCT				
	A6	WO 95/32671	12/95	PCT				
	B6	WO 95/32669	12/95	PCT				
	C6	WO 96/24290	08/96	PCT				

Page 7 of 7

Form PTO 1449 (Rev. 2-32) U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 34298-122	Serial No. 10/068,812
Information Disclosure Statement by Applicant		Applicant: Richard J. Greff	
(Use several sheets if necessary)		Filed: 02/04/02	Group: 1615
	D6	Schievink, et al. The new england journal of medicaine; review articles; intracranial aneurysms; Jan. 2 1997	
	E6	Scharader, R. "Collagen appl.", Catheterization & cardiovascular diagnosis (1992) pp. 298-302	
	F6	Silber, S., "Rapid hemostasis of arterial puncture sites with collagen in patients undergoing diagnostic interventional cardiac cathererization", clinical cardiology, vol. 20, pp. 981-992, (1997)	
	G6	Smith, T., "Percutaneous transhepatic liver biopsy with tract embolization", Radiology, vol. 198, pp. 769-774 (1996)	

	H6	Szikora, et al. Combined Use of stents and cells to treat experimental wide-necked carotid aneurysms: Preliminary results; AJNR AM newradiol 15: 1091-1102, June 94
	I6	Szikora, et al. Endovascular treatment of experimental aneuerysms with liquid polymers: vol. 38, no. 2, Feb. 96
	J6	Turjman, et al. Combined stent implantation & endosacular coil placement for tretment of experimental wide-necked aneurysms: AJNRAM J. Neuroradio 15: 1087-1090 June 94
	K6	Yoshimoto, et al cerebral aneuerysms unrelated to arterial bifurcations; Acta neurochir (Wien) (96) 138: 958-964

	L6	Zins, M., "US-guided percutaneous liver biopsy with plugging of the needle track" radiology, vol. 187, pp. 841-843, (1992)

Examiner	Date Considered
Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.	